Email Archive

Arthritis Breakthrough

Score 0.698 · Account tjphuhs@gmail.com · 4/21/2026, 9:11:52 AM

Arthritis Breakthrough from news@twc.health on 2026-04-21T13:11:52.000Z Read why scientists are excited about Ivermectin’s anti-inflammatory power This email was sent to you as HTML-only. To view it, please visit: https://arn.soundestlink.com/ce/v/66f59766ed7d70230df9f78b/69e67db565142cea1a702b60 ************************** Make sure you keep getting our latest offers and add news@twc.health to your address book. Unsubscribe https://arn.soundestlink.com/contactsPreferences/v2/unsubscribe/?b=6480d

The GLP-1 Moment Is Breaking the Healthcare System Wide Open

Score 0.558 · Account tjphuhs@gmail.com · 3/18/2026, 6:27:27 PM

The GLP-1 Moment Is Breaking the Healthcare System Wide Open from onthepen@substack.com on 2026-03-18T22:27:27.000Z View this post on the web at https://onthepen.substack.com/p/the-glp-1-moment-is-breaking-the I’ve said this a number of times, but it keeps proving itself out. GLP-1 medications are not just transforming lives, they’re transforming our healthcare system in a way we haven’t seen in decades, and it’s happening faster than most people realize. What started as a shortage story, and on

Fwd: Urolithin A: The Most Underrated Compound in Longevity

Score 0.540 · Account tjphuhs@gmail.com · 5/2/2026, 4:58:06 PM

Fwd: Urolithin A: The Most Underrated Compound in Longevity from tjphuhs@gmail.com on 2026-05-02T20:58:06.000Z doesn’t get enough attention. UA crosses the blood-brain barrier, and the preclinical neuroprotective data is genuinely impressive across multiple disease models. > Alzheimer’s disease (preclinical) > In multiple AD mouse models — APP/PS1, 3xTgAD, and DNA-repair-deficient ADP mice — UA treatment has been shown to: > > • > Reduce amyloid-beta plaque accumulation > • > Decrease tau hyperp

Fwd: Urolithin A: The Most Underrated Compound in Longevity

Score 0.540 · Account oc.tjphuhs@gmail.com · 5/2/2026, 4:58:06 PM

Fwd: Urolithin A: The Most Underrated Compound in Longevity from tjphuhs@gmail.com on 2026-05-02T20:58:06.000Z doesn’t get enough attention. UA crosses the blood-brain barrier, and the preclinical neuroprotective data is genuinely impressive across multiple disease models. > Alzheimer’s disease (preclinical) > In multiple AD mouse models — APP/PS1, 3xTgAD, and DNA-repair-deficient ADP mice — UA treatment has been shown to: > > • > Reduce amyloid-beta plaque accumulation > • > Decrease tau hyperp

Fwd: New Study Worth Knowing About: GLP-1s and Alzheimer's

Score 0.539 · Account tjphuhs@gmail.com · 4/30/2026, 11:00:22 AM

Fwd: New Study Worth Knowing About: GLP-1s and Alzheimer's from tjphuhs@gmail.com on 2026-04-30T15:00:22.000Z wave of trials needs to recruit at-risk people before symptoms start — that’s where the real test happens. > This is one more data point worth tracking as the field develops. Stay measured, watch the next 2-3 years of trial readouts, and don’t get ahead of the evidence. > Drop questions or thoughts below. > Disclaimer: This content is for research and educational purposes only and is not

Fwd: New Study Worth Knowing About: GLP-1s and Alzheimer's

Score 0.539 · Account oc.tjphuhs@gmail.com · 4/30/2026, 11:00:22 AM

Fwd: New Study Worth Knowing About: GLP-1s and Alzheimer's from tjphuhs@gmail.com on 2026-04-30T15:00:22.000Z wave of trials needs to recruit at-risk people before symptoms start — that’s where the real test happens. > This is one more data point worth tracking as the field develops. Stay measured, watch the next 2-3 years of trial readouts, and don’t get ahead of the evidence. > Drop questions or thoughts below. > Disclaimer: This content is for research and educational purposes only and is not

Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine

Score 0.537 · Account oc.tjphuhs@gmail.com · 4/24/2026, 9:42:34 AM

Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from tjphuhs@gmail.com on 2026-04-24T13:42:34.000Z 20.1% weight loss at 48 weeks in Phase 2 — as a standalone drug. Novo Nordisk’s CagriSema combines semaglutide with an amylin agonist for this exact reason. Amylin is a proven target. > Calcitonin > This is the most interesting addition, and the one most worth understanding in depth. > Calcitonin is a hormone your thyroid produces that’s been known for decades primarily

Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine

Score 0.537 · Account tjphuhs@gmail.com · 4/24/2026, 9:42:34 AM

Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from tjphuhs@gmail.com on 2026-04-24T13:42:34.000Z 20.1% weight loss at 48 weeks in Phase 2 — as a standalone drug. Novo Nordisk’s CagriSema combines semaglutide with an amylin agonist for this exact reason. Amylin is a proven target. > Calcitonin > This is the most interesting addition, and the one most worth understanding in depth. > Calcitonin is a hormone your thyroid produces that’s been known for decades primarily

Urolithin A: The Most Underrated Compound in Longevity

Score 0.535 · Account tjphuhs@gmail.com · 5/2/2026, 11:16:56 AM

Urolithin A: The Most Underrated Compound in Longevity from derekpruski@substack.com on 2026-05-02T15:16:56.000Z which collectively drive expression of antioxidant defense genes and reduce oxidative stress. Mechanisms Relevant to Neurodegeneration This is the section that doesn’t get enough attention. UA crosses the blood-brain barrier, and the preclinical neuroprotective data is genuinely impressive across multiple disease models. Alzheimer’s disease (preclinical) In multiple AD mouse models —

Peg MGF: The Underrated Healing Peptide

Score 0.534 · Account tjphuhs@gmail.com · 5/1/2026, 10:49:22 AM

Peg MGF: The Underrated Healing Peptide from derekpruski@substack.com on 2026-05-01T14:49:22.000Z systemically in research models. They circulate, they bind receptors throughout the body, and they drive broad growth signaling. That’s also why they raise concerns in the literature around long-term proliferation in tissues where you wouldn’t want it. MGF is a splice variant of the same IGF-1 gene, but it has a different C-terminal sequence (called the Ec peptide in humans). That different tail end

Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine

Score 0.533 · Account tjphuhs@gmail.com · 4/24/2026, 9:05:46 AM

Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from derekpruski@substack.com on 2026-04-24T13:05:46.000Z have better tolerability than incretins, with less nausea Lilly’s eloralintide (a selective amylin agonist) showed up to 20.1% weight loss at 48 weeks in Phase 2 — as a standalone drug. Novo Nordisk’s CagriSema combines semaglutide with an amylin agonist for this exact reason. Amylin is a proven target. Calcitonin This is the most interesting addition, and the one most

New Study Worth Knowing About: GLP-1s and Alzheimer's

Score 0.529 · Account tjphuhs@gmail.com · 4/30/2026, 10:19:32 AM

New Study Worth Knowing About: GLP-1s and Alzheimer's from derekpruski@substack.com on 2026-04-30T14:19:32.000Z gets exciting: 22 out of 30 studies showed reductions in amyloid-beta plaques 19 out of 30 studies showed reductions in tau tangles That’s about 73% showing plaque reduction and 63% showing tangle reduction. In research terms, that’s a strong, consistent signal — not a one-off finding. By drug: Liraglutide — the most studied of the four. The most consistent. Reduced both plaques AND ta

New Study Worth Knowing About: GLP-1s and Alzheimer's

Score 0.529 · Account tjphuhs@gmail.com · 4/30/2026, 10:19:32 AM

New Study Worth Knowing About: GLP-1s and Alzheimer's from derekpruski@substack.com on 2026-04-30T14:19:32.000Z below. Disclaimer: This content is for research and educational purposes only and is not medical advice. All compounds discussed (peptides, GLP-1 receptor agonists, and related research chemicals) are referenced in the context of research use only (RUO) and the published scientific literature. Nothing in this post should be interpreted as a recommendation for human consumption, diagnos

TB-500 for Alzheimer's?

Score 0.527 · Account tjphuhs@gmail.com · 3/30/2026, 6:07:48 PM

TB-500 for Alzheimer's? from huntershealthhacks@mail.beehiiv.com on 2026-03-30T22:07:48.000Z 5xFAD mice. In the novel object recognition test, treated mice showed better ability to distinguish new objects from familiar ones. Their memory was measurably improved. Then the researchers examined what was happening in the brains of these mice. Analysis showed that glial activation was markedly reduced in treated mice. That means microglia and astrocytes were less inflamed. Neuronal apoptosis was also

The GLP-1 Moment Is Breaking the Healthcare System Wide Open

Score 0.526 · Account tjphuhs@gmail.com · 3/18/2026, 6:27:27 PM

The GLP-1 Moment Is Breaking the Healthcare System Wide Open from onthepen@substack.com on 2026-03-18T22:27:27.000Z are doing at the individual level is just as profound. They are increasingly looking like longevity drugs, fewer heart attacks and strokes, less inflammation, reduced cancer risk signals, meaningful diabetes improvement, and the list keeps growing. The impact of that alone is massively transformative and cannot be overstated. I’ve been digging into this more in recent conversations

Peg MGF: The Underrated Healing Peptide

Score 0.526 · Account tjphuhs@gmail.com · 5/1/2026, 10:49:22 AM

Peg MGF: The Underrated Healing Peptide from derekpruski@substack.com on 2026-05-01T14:49:22.000Z one of those compounds that doesn’t get much attention because the use case isn’t flashy. There aren’t dramatic before-and-after research results from a Peg MGF protocol. But for injury research specifically — especially involving muscle-tissue damage — it covers a mechanistic gap that BPC, TB-500, KPV, and Cartalax don’t directly address. If the research model involves actual muscle damage (strain,

Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine

Score 0.525 · Account tjphuhs@gmail.com · 4/24/2026, 9:42:34 AM

Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from tjphuhs@gmail.com on 2026-04-24T13:42:34.000Z > • > News-Medical coverage: “New quintuple agonist shows promise for treating obesity and type 2 diabetes.” September 21, 2025. news-medical.net > • > Andreassen KV, et al. Research on Dual Amylin and Calcitonin Receptor Agonists (DACRAs, KBP-042, KBP-089) — various publications > • > Eli Lilly pipeline page (no quintuple currently listed): lilly.com/science/research-de

Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine

Score 0.525 · Account oc.tjphuhs@gmail.com · 4/24/2026, 9:42:34 AM

Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from tjphuhs@gmail.com on 2026-04-24T13:42:34.000Z > • > News-Medical coverage: “New quintuple agonist shows promise for treating obesity and type 2 diabetes.” September 21, 2025. news-medical.net > • > Andreassen KV, et al. Research on Dual Amylin and Calcitonin Receptor Agonists (DACRAs, KBP-042, KBP-089) — various publications > • > Eli Lilly pipeline page (no quintuple currently listed): lilly.com/science/research-de

Fwd: GW501516 (Cardarine) — Full Research Breakdown: Mechanisms, Cancer Data, and What the Human Trials Actually Show

Score 0.520 · Account tjphuhs@gmail.com · 3/26/2026, 11:39:28 AM

Fwd: GW501516 (Cardarine) — Full Research Breakdown: Mechanisms, Cancer Data, and What the Human Trials Actually Show from tjphuhs@gmail.com on 2026-03-26T15:39:28.000Z networks. European Heart Journal, 34(23):1755-65. > • > Li, S. et al. (2015). Exercise Pills: At the Starting Line. Trends in Pharmacological Sciences, 36(12):906-917. > • > Grewal, A.S. et al. (2016). Recent Updates on PPARδ Agonists for the Treatment of Metabolic Syndrome. Journal of Medicinal Chemistry, 12(1):3-21. > • > Wall,

Fwd: GW501516 (Cardarine) — Full Research Breakdown: Mechanisms, Cancer Data, and What the Human Trials Actually Show

Score 0.520 · Account oc.tjphuhs@gmail.com · 3/26/2026, 11:39:28 AM

Fwd: GW501516 (Cardarine) — Full Research Breakdown: Mechanisms, Cancer Data, and What the Human Trials Actually Show from tjphuhs@gmail.com on 2026-03-26T15:39:28.000Z networks. European Heart Journal, 34(23):1755-65. > • > Li, S. et al. (2015). Exercise Pills: At the Starting Line. Trends in Pharmacological Sciences, 36(12):906-917. > • > Grewal, A.S. et al. (2016). Recent Updates on PPARδ Agonists for the Treatment of Metabolic Syndrome. Journal of Medicinal Chemistry, 12(1):3-21. > • > Wall,

Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine

Score 0.518 · Account oc.tjphuhs@gmail.com · 4/24/2026, 9:42:34 AM

Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from tjphuhs@gmail.com on 2026-04-24T13:42:34.000Z PPAR part is only released inside cells that express GLP-1 or GIP receptors, so it’s targeted rather than systemic. > Mouse models showed it outperformed GLP-1/GIP co-agonism alone on both weight and glucose control. > This is academic preclinical work — not owned by Lilly, not in human trials — but it demonstrates that pushing past three receptor targets is a legitimate

Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine

Score 0.518 · Account tjphuhs@gmail.com · 4/24/2026, 9:42:34 AM

Fwd: Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicine from tjphuhs@gmail.com on 2026-04-24T13:42:34.000Z PPAR part is only released inside cells that express GLP-1 or GIP receptors, so it’s targeted rather than systemic. > Mouse models showed it outperformed GLP-1/GIP co-agonism alone on both weight and glucose control. > This is academic preclinical work — not owned by Lilly, not in human trials — but it demonstrates that pushing past three receptor targets is a legitimate

Fwd: Bryan Johnson’s adaptogen protocol

Score 0.518 · Account tjphuhs@gmail.com · 3/20/2026, 4:23:45 PM

Fwd: Bryan Johnson’s adaptogen protocol from tjphuhs@gmail.com on 2026-03-20T20:23:45.000Z ---------- Forwarded message ---------- From: Blueprint <hello@bryanjohnson.com> Date: Mar 20, 2026 at 4:02 PM -0400 To: tjphuhs@gmail.com Subject: Bryan Johnson’s adaptogen protocol > research-backed benefits ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏

Fwd: New Study Worth Knowing About: GLP-1s and Alzheimer's

Score 0.518 · Account tjphuhs@gmail.com · 4/30/2026, 11:00:22 AM

Fwd: New Study Worth Knowing About: GLP-1s and Alzheimer's from tjphuhs@gmail.com on 2026-04-30T15:00:22.000Z That’s about 73% showing plaque reduction and 63% showing tangle reduction. In research terms, that’s a strong, consistent signal — not a one-off finding. > By drug: > > • > Liraglutide — the most studied of the four. The most consistent. Reduced both plaques AND tangles across multiple models. > • > Dulaglutide — fewer studies, but consistent. Reduced both plaques and tangles, and impro

Fwd: New Study Worth Knowing About: GLP-1s and Alzheimer's

Score 0.518 · Account oc.tjphuhs@gmail.com · 4/30/2026, 11:00:22 AM

Fwd: New Study Worth Knowing About: GLP-1s and Alzheimer's from tjphuhs@gmail.com on 2026-04-30T15:00:22.000Z That’s about 73% showing plaque reduction and 63% showing tangle reduction. In research terms, that’s a strong, consistent signal — not a one-off finding. > By drug: > > • > Liraglutide — the most studied of the four. The most consistent. Reduced both plaques AND tangles across multiple models. > • > Dulaglutide — fewer studies, but consistent. Reduced both plaques and tangles, and impro